RESUMEN
Excessive inflammatory reactions caused by uric acid deposition are the key factor leading to gout. However, clinical medications cannot simultaneously remove uric acid and eliminate inflammation. An M2 macrophage-erythrocyte hybrid membrane-camouflaged biomimetic nanosized liposome (USM[H]L) is engineered to deliver targeted self-cascading bienzymes and immunomodulators to reprogram the inflammatory microenvironment in gouty rats. The cell-membrane-coating endow nanosomes with good immune escape and lysosomal escape to achieve long circulation time and intracellular retention times. After being uptaken by inflammatory cells, synergistic enzyme-thermo-immunotherapies are achieved: uricase and nanozyme degraded uric acid and hydrogen peroxide, respectively; bienzymes improved the catalytic abilities of each other; nanozyme produced photothermal effects; and methotrexate has immunomodulatory and anti-inflammatory effects. The uric acid levels markedly decrease, and ankle swelling and claw curling are effectively alleviated. The levels of inflammatory cytokines and ROS decrease, while the anti-inflammatory cytokine levels increase. Proinflammatory M1 macrophages are reprogrammed to the anti-inflammatory M2 phenotype. Notably, the IgG and IgM levels in USM[H]L-treated rats decrease substantially, while uricase-treated rats show high immunogenicity. Proteomic analysis show that there are 898 downregulated and 725 upregulated differentially expressed proteins in USM[H]L-treated rats. The protein-protein interaction network indicates that the signaling pathways include the spliceosome, ribosome, purine metabolism, etc.
Asunto(s)
Urato Oxidasa , Ácido Úrico , Ratas , Animales , Ácido Úrico/metabolismo , Ácido Úrico/farmacología , Urato Oxidasa/metabolismo , Urato Oxidasa/farmacología , Biomimética , Proteómica , Macrófagos/metabolismo , Inflamación/metabolismo , Citocinas/metabolismo , Antiinflamatorios/farmacología , Membrana Eritrocítica/metabolismo , InmunoterapiaRESUMEN
AIM: Jian Pi Shen Shi Formula (JPSSF) is a beneficial treatment for hyperuricemia and related tissue damage in the clinical setting. This study was designed to investigate its therapeutic potential and underlying mechanisms in uricase-deficient rats (Uox-/- rats). METHODS: Uox-/- rats were used to assess the therapeutic potential of JPSSF on hyperuricemia. Protein extracts from renal tissues of a Uox-/- group and a JPSSF group were analyzed using tandem mass tag labeling quantitative proteomic workflow. Collagen deposition in Uox-/- rat kidneys was analyzed by Masson trichromatic staining. The gene expression associated with collagen-binding-related signaling pathways in the kidneys was further explored using quantitative polymerase chain reaction assay. The protein expressions of collagen 1a1 (col1a1), col6a1, and α-smooth muscle actin were measured by Western blotting and immunohistochemistry. RESULTS: JPSSF significantly decreased renal function indices and alleviated renal injuries. The action of JPSSF was manifested by down-regulation of col6a1 and interleukin-1 receptor-associated kinase-like 2, which blocked the binding sites on collagen and further prevented kidney injury. The anti-renal fibrosis effect of JPSSF was confirmed by reducing the collagen deposition and hydroxyproline concentrations. JPSSF treatment also intensely down-regulated the mRNA and protein expressions of col6a1, col1a1, and α-smooth muscle actin, which inhibited the function of the collagen-binding-related signaling pathway. CONCLUSION: Our results indicated that JPSSF notably ameliorated hyperuricemia and related renal fibrosis in Uox-/- rats through lowering uric acid and down-regulating the function of the collagen-binding pathway. This suggested that JPSSF is a potential empirical formula for treating hyperuricemia and accompanying renal fibrosis.
Asunto(s)
Hiperuricemia , Enfermedades Renales , Ratas , Animales , Hiperuricemia/complicaciones , Hiperuricemia/tratamiento farmacológico , Urato Oxidasa/metabolismo , Urato Oxidasa/farmacología , Urato Oxidasa/uso terapéutico , Actinas/metabolismo , Proteómica , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/etiología , Enfermedades Renales/prevención & control , Fibrosis , Riñón/patología , Transducción de Señal , Colágeno/metabolismoRESUMEN
Biologic drugs have transformed the standard of care for many diseases. However, many biologics induce the formation of anti-drug antibodies (ADAs), which can compromise their safety and efficacy. Preclinical studies demonstrate that biodegradable nanoparticles-encapsulating rapamycin (ImmTOR), but not free rapamycin, mitigate the immunogenicity of co-administered biologic drugs. Here we report the outcomes from two clinical trials for ImmTOR. In the first ascending dose, open-label study (NCT02464605), pegadricase, an immunogenic, pegylated uricase enzyme derived from Candida utilis, is assessed for safety and tolerability (primary endpoint) as well as activity and immunogenicity (secondary endpoint); in the second single ascending dose Phase 1b trial (NCT02648269) composed of both a double-blind and open-label parts, we evaluate the safety of ImmTOR (primary endpoint) and its ability to prevent the formation of anti-drug antibodies against pegadricase and enhance its pharmacodynamic activity (secondary endpoint) in patients with hyperuricemia. The combination of ImmTOR and pegadricase is well tolerated. ImmTOR inhibits the development of uricase-specific ADAs in a dose-dependent manner, thus enabling sustained enzyme activity and reduction in serum uric acid levels. ImmTOR may thus represent a feasible approach for preventing the formation of ADAs to a broad range of immunogenic biologic therapies.
Asunto(s)
Anticuerpos/uso terapéutico , Hiperuricemia/tratamiento farmacológico , Nanopartículas/química , Nanopartículas/uso terapéutico , Polietilenglicoles/farmacología , Urato Oxidasa/uso terapéutico , Adulto , Anciano , Anticuerpos/química , Terapia Biológica , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Compuestos Orgánicos/química , Urato Oxidasa/farmacología , Ácido Úrico , Adulto JovenRESUMEN
OBJECTIVE: Management of hyperuricemia is crucial to controlling tumor lysis syndrome (TLS) during cancer therapy. Urate oxidase (UOX) that catalyzes the enzymatic oxidation of uric acid into allantoin, is effective in lowering plasma uric acid levels and controlling hyperuricemia. Recently, we developed a new recombinant conjugate variant of UOX therapeutic drug using PASylation technology. This study was designed to evaluate the stability, plasma half-life and immunogencity of PASylated UOX. METHODS: A recombinant variant of PASylated UOX from the Aspergillus flavus was manufactured using bioinformatics and experimental techniques. Ex vivo evaluation of stability of PASylated UOX was done in 50% human serum. For half-life test, recombinant PASylated UOX and rasburicase were administered at 1.5 mg/kg to 10 rats in two different groups and samples were collected after injection Production of antibodies against PASylated drug was also assayed. RESULTS: Residual activity of PASylated UOX in 50% human serum was higher than rasburicase and native UOX. Stability of PASylated UOX at 25°C and 37°C was also higher than rasburicase and native UOX. The PASylated half-life was ~32.1 hours, whereas half-life for rasburicase and native UOX was ~25.1 and ~22.8 hours, respectively. In immunogenicity examination, there is 33% and 36% decrease in the absorbance of native UOX and rasburicase, respectively when compared with that of PASylated UOX. CONCLUSION: Our data confirmed the efficacy and stability of PASylated UOX in comparison to the rasburicase. In summary, the results indicated that PASylated UOX drug is effective at lowering plasma uric acid levels with prolonged plasma half-life and decreased cost.
.
Asunto(s)
Hiperuricemia/tratamiento farmacológico , Urato Oxidasa/farmacología , Animales , Estabilidad de Medicamentos , Semivida , Humanos , Hiperuricemia/sangre , Ratas , Proteínas RecombinantesRESUMEN
ABSTRACT: Secondary brain injury following hemorrhagic shock (HS) is a frequent complication in patients, even in the absence of direct brain trauma, leading to behavioral changes and more specifically anxiety and depression. Despite preclinical studies showing inflammation and apoptosis in the brain after HS, none have addressed the impact of circulating mediators. Our group demonstrated an increased uric acid (UA) circulation in rats following HS. Since UA is implicated in endothelial dysfunction and inflammatory response, we hypothesized UA could alter the blood-brain barrier (BBB) and impact the brain. Male Wistar rats were randomly assigned to: SHAM, HS (hemorrhagic shock) and HSâ+âU (hemorrhagic shock + 1.5âmg/kg of uricase). The uricase intervention, specifically targeting UA, was administered during fluid resuscitation. It prevented BBB dysfunction (fluorescein sodium salt permeability and expression of intercellular adhesion molecule-1) following HS. As for neuroinflammation, all of the results obtained (MPO activity; Iba1 and GFAP expression) showed a significant increase after HS, also prevented by the uricase. The same pattern was observed after quantification of apoptosis (caspase-3 activity and TUNEL) and neurodegeneration (Fluoro-Jade). Finally, the forced swim, elevated plus maze, and social interaction tests detected anxiety-like behavior after HS, which was blunted in rats treated with the uricase. In conclusion, we have identified UA as a new circulatory inflammatory mediator, responsible for brain alterations and anxious behavior after HS in a murine model. The ability to target UA holds the potential of an adjunctive therapeutic solution to reduce brain dysfunction related to hemorrhagic shock in human.
Asunto(s)
Ansiedad/prevención & control , Lesiones Encefálicas/prevención & control , Mediadores de Inflamación/antagonistas & inhibidores , Choque Hemorrágico/prevención & control , Urato Oxidasa/farmacología , Urato Oxidasa/uso terapéutico , Ácido Úrico/antagonistas & inhibidores , Animales , Lesiones Encefálicas/etiología , Modelos Animales de Enfermedad , Masculino , Distribución Aleatoria , Ratas , Ratas Wistar , Choque Hemorrágico/complicacionesRESUMEN
BACKGROUND: Tumor lysis syndrome (TLS) is a metabolic emergency in hematology patients. The recommended dose of rasburicase for the management of TLS is 0.2 mg/kg per day for 5 days, which is cost prohibitive for many patients. We sought to determine the efficacy of single low-dose rasburicase in the prevention and treatment of hyperuricemia in TLS. PATIENTS AND METHODS: We planned a prospective study for the safety and efficacy of fixed (weight based) dose of rasburicase to manage TLS. Patients diagnosed with leukemia/lymphoma with laboratory or clinically confirmed TLS or presence of ≥ 2 high-risk factors and serum uric acid > 7.5 mg/dL were included. The primary endpoint was uric acid normalization (< 7.5 mg/dL) within 24 hours of rasburicase administration. RESULTS: Fifty-five patients were recruited for this study. Pediatric patients (< 18 years) accounted for 43.6% of cases. Rasburicase was provided prophylactically to 43 patients (78.2%) and for treating TLS to 12 (21.8%). Mean ± standard deviation serum uric acid at baseline and 24 hours was 9.2 ± 1.8 mg/dL and 3.2 ± 2.1 mg/dL, respectively. There was significant reduction in the serum uric acid and creatinine (P < .001) within 24 hours of rasburicase administration. The response was maintained up to 72 hours. A single dose of rasburicase was effective in 94.5% of patients. Single low-dose rasburicase led to 95% direct cost savings compared to the recommended dose. CONCLUSION: Single-dose rasburicase with frequent laboratory monitoring is effective in the management of TLS and offers significant cost reductions.
Asunto(s)
Leucemia/complicaciones , Linfoma/complicaciones , Proteínas Recombinantes/uso terapéutico , Síndrome de Lisis Tumoral/tratamiento farmacológico , Urato Oxidasa/uso terapéutico , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Leucemia/tratamiento farmacológico , Linfoma/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Proteínas Recombinantes/farmacología , Resultado del Tratamiento , Urato Oxidasa/farmacología , Adulto JovenRESUMEN
Gout is currently the most frequent cause of inflammatory arthritis worldwide. It results from elevated serum urate and subsequent deposition of monosodium urate crystals in joints and other tissues. While many patients with gout can be managed with conventional agents (e.g., allopurinol, febuxostat), those with chronic refractory gout often fail to achieve treatment goals with these agents. Pegloticase is a recombinant, pegylated mammalian uricase developed for treatment of chronic refractory gout. Pegloticase is different than other urate lowering therapies in that it enzymatically degrades urate. Pegloticase has been evaluated in multiple studies, most importantly in two randomized controlled trials and a follow-up open-label extension. Extensive analysis of results from these studies has shown that pegloticase profoundly lowers serum urate, resolves tophi, reduces tender and swollen joint counts, decreases pain, and improves both patients' global assessments and quality of life. Pegloticase also significantly decreases blood pressure in patients with chronic refractory gout, but has no significant effect on renal function. Post hoc analyses of clinical results also indicated that chronic refractory gout patients not achieving sustained urate lowering still have significant clinical benefits with pegloticase treatment. The major limitation of pegloticase is immunogenicity and the emergence of anti-drug antibodies that result in increased drug clearance, loss of efficacy, and infusion reactions. However, these reactions can be avoided by stopping pegloticase when there is a loss of serum urate lowering. New dosing regimens and co-administration of immunosuppressive agents are also being employed to overcome this limitation and extend the benefits of pegloticase to a larger number of patients.
Asunto(s)
Artritis Gotosa/tratamiento farmacológico , Supresores de la Gota/uso terapéutico , Polietilenglicoles/uso terapéutico , Urato Oxidasa/uso terapéutico , Enfermedad Crónica , Supresores de la Gota/farmacología , Humanos , Polietilenglicoles/farmacología , Brote de los Síntomas , Urato Oxidasa/farmacologíaRESUMEN
Background Uric acid (UA) is a plasmatic antioxidant that has possible effects on blood pressure. The effects of UA on endothelial function are unclear. We hypothesize that endothelial function is not impaired unless significant UA depletion is achieved through selective xanthine oxidase inhibition with febuxostat and recombinant uricase (rasburicase). Methods and Results Microvascular hyperemia, induced by iontophoresis of acetylcholine and sodium nitroprusside, and heating-induced local hyperemia after iontophoresis of saline and a specific nitric oxide synthase inhibitor were assessed by laser Doppler imaging. Blood pressure and renin-angiotensin system markers were measured, and arterial stiffness was assessed. CRP (C-reactive protein), allantoin, chlorotyrosine/tyrosine ratio, homocitrulline/lysine ratio, myeloperoxidase activity, malondialdehyde, and interleukin-8 were used to characterize inflammation and oxidative stress. Seventeen young healthy men were enrolled in a randomized, double-blind, placebo-controlled, 3-way crossover study. The 3 compared conditions were placebo, febuxostat alone, and febuxostat together with rasburicase. The allantoin (µmol/L)/UA (µmol/L) ratio differed between sessions (P<0.0001). During the febuxostat-rasburicase session, heating-induced hyperemia became altered in the presence of nitric oxide synthase inhibition; and systolic blood pressure, angiotensin II, and myeloperoxidase activity decreased (P≤0.03 versus febuxostat). The aldosterone concentration decreased in the febuxostat-rasburicase group (P=0.01). Malondialdehyde increased when UA concentration decreased (both P<0.01 for febuxostat and febuxostat-rasburicase versus placebo). Other parameters remained unchanged. Conclusions A large and short-term decrease in UA in humans alters heat-induced endothelium-dependent microvascular vasodilation, slightly reduces systolic blood pressure through renin-angiotensin system activity reduction, and markedly reduces myeloperoxidase activity when compared with moderate UA reduction. A moderate or severe hypouricemia leads to an increase in lipid peroxidation through loss of antioxidant capacity of plasma. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT03395977.
Asunto(s)
Presión Sanguínea/fisiología , Endotelio Vascular/fisiopatología , Febuxostat/farmacología , Microvasos/fisiopatología , Urato Oxidasa/farmacología , Ácido Úrico/sangre , Vasodilatación/fisiología , Xantina Oxidasa/antagonistas & inhibidores , Adulto , Estudios Cruzados , Método Doble Ciego , Endotelio Vascular/enzimología , Humanos , Masculino , Microvasos/enzimología , Índice de Severidad de la Enfermedad , Adulto JovenAsunto(s)
Gota/tratamiento farmacológico , Polietilenglicoles/uso terapéutico , Urato Oxidasa/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Gota/complicaciones , Gota/metabolismo , Humanos , Peróxido de Hidrógeno/metabolismo , Polietilenglicoles/farmacología , Urato Oxidasa/farmacología , Ácido Úrico/metabolismoRESUMEN
Uric acid has been linked with increased risk of chronic disease such as cardiovascular disease and this association has been attributed to a pro-inflammatory effect. Indeed, observational studies have shown that high uric acid is associated with high level of pro-inflammatory cytokines in the blood. However, whether high uric acid directly affects inflammation or rather represents a parallel defensive antioxidant mechanism in response to pathology that causes inflammation is unknown. To determine whether acute increase or decrease uric acid levels affects inflammation in healthy individuals, a randomized, placebo-controlled, double blind clinical study of uric acid or rasburicase with 20 healthy volunteers in each treatment-placebo group was conducted at the National Institute on Aging (NIA) Clinical Research Unit (CRU) at Harbor Hospital in Baltimore, MD. Change in inflammatory response was assessed by administering an oral lipid tolerance before and after the treatment of uric acid, rasburicase and placebo. Following uric acid administration, there was an accentuated increase in IL-6 during the oral lipid tolerance test (P<0.001). No significant differences were observed after lowering of uric acid with rasburicase. No side effects were reported throughout the trial. In health individuals, acute increase in uric acid results in an increased IL-6 response when challenged with lipid load. Such effect of amplification of inflammatory response may explain the higher risk of chronic diseases observed in subclinical hyperuricemia in observational studies. TRIAL REGISTRATION: ClinicalTrials.gov NCT01323335.
Asunto(s)
Interleucina-6/sangre , Urato Oxidasa/farmacología , Ácido Úrico/sangre , Ácido Úrico/farmacología , Biomarcadores/sangre , Método Doble Ciego , Femenino , Expresión Génica/efectos de los fármacos , Humanos , Inflamación/sangre , Lípidos/administración & dosificación , Masculino , Análisis por Micromatrices , Persona de Mediana Edad , Proyectos PilotoRESUMEN
Rasburicase has a strong and fast effect for reducing blood levels of uric acid. However, there have been no reports of theoretical analysis for the rational dose and interval of administration. Thus we constructed a pharmacokinetic and pharmacodynamic model to determine changes in uric acid level after rasburicase administration at various doses and regimens. The time courses of uric acid level predicted using our model were in good agreement with observed data, indicating adequate performance for our model. The therapeutic effects after a single infusion at various rates of generation of uric acid were predicted. The maximum effect was not a large difference, in spite of the generation rate. Then, the therapeutic effects of repeated administrations were predicted. The effect did not change when rasburicase was administered at more than the usual dose. Besides, as the administration interval increased, the difference between minimum and maximum level of uric acid became greater. However, in all doses and regimens, adequate therapeutic effects were obtained. In conclusion, the model was found useful for predicting therapeutic effect of rasburicase and individually determining rational dosage regimen of rasburicase.
Asunto(s)
Supresores de la Gota/farmacocinética , Supresores de la Gota/uso terapéutico , Hiperuricemia/tratamiento farmacológico , Modelos Biológicos , Urato Oxidasa/farmacocinética , Urato Oxidasa/uso terapéutico , Antineoplásicos/efectos adversos , Supresores de la Gota/administración & dosificación , Supresores de la Gota/farmacología , Humanos , Hiperuricemia/inducido químicamente , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Urato Oxidasa/administración & dosificación , Urato Oxidasa/farmacología , Ácido Úrico/sangreRESUMEN
INTRODUCTION: Uric acid released from injured tissue is considered a major endogenous danger signal and local instillation of uric acid crystals induces acute lung inflammation via activation of the NLRP3 inflammasome. Ventilator-induced lung injury (VILI) is mediated by the NLRP3 inflammasome and increased uric acid levels in lung lavage fluid are reported. We studied levels in human lung injury and the contribution of uric acid in experimental VILI. METHODS: Uric acid levels in lung lavage fluid of patients with acute lung injury (ALI) were determined. In a different cohort of cardiac surgery patients, uric acid levels were correlated with pulmonary leakage index. In a mouse model of VILI the effect of allopurinol (inhibits uric acid synthesis) and uricase (degrades uric acid) pre-treatment on neutrophil influx, up-regulation of adhesion molecules, pulmonary and systemic cytokine levels, lung pathology, and regulation of receptors involved in the recognition of uric acid was studied. In addition, total protein and immunoglobulin M in lung lavage fluid and pulmonary wet/dry ratios were measured as markers of alveolar barrier dysfunction. RESULTS: Uric acid levels increased in ALI patients. In cardiac surgery patients, elevated levels correlated significantly with the pulmonary leakage index. Allopurinol or uricase treatment did not reduce ventilator-induced inflammation, IκB-α degradation, or up-regulation of NLRP3, Toll-like receptor 2, and Toll-like receptor 4 gene expression in mice. Alveolar barrier dysfunction was attenuated which was most pronounced in mice pre-treated with allopurinol: both treatment strategies reduced wet/dry ratio, allopurinol also lowered total protein and immunoglobulin M levels. CONCLUSIONS: Local uric acid levels increase in patients with ALI. In mice, allopurinol and uricase attenuate ventilator-induced alveolar barrier dysfunction.
Asunto(s)
Alopurinol/farmacología , Alveolos Pulmonares/efectos de los fármacos , Alveolos Pulmonares/fisiopatología , Urato Oxidasa/farmacología , Lesión Pulmonar Inducida por Ventilación Mecánica/tratamiento farmacológico , Lesión Pulmonar Inducida por Ventilación Mecánica/fisiopatología , Lesión Pulmonar Aguda/metabolismo , Adulto , Alopurinol/uso terapéutico , Animales , Líquido del Lavado Bronquioalveolar , Permeabilidad Capilar/efectos de los fármacos , Proteínas Portadoras/genética , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Proteínas I-kappa B/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Microvasos/efectos de los fármacos , Microvasos/metabolismo , Inhibidor NF-kappaB alfa , Proteína con Dominio Pirina 3 de la Familia NLR , Receptor Toll-Like 2/genética , Receptor Toll-Like 4/genética , Urato Oxidasa/uso terapéutico , Ácido Úrico/metabolismo , Lesión Pulmonar Inducida por Ventilación Mecánica/metabolismoRESUMEN
OBJECTIVE: Previous studies on various enzymosomes (functional lipid vesicles encapsulating an enzyme) have been mostly carried out in vitro and have focused on preserving catalytic activity and improving the stability of the enzyme. Until now, few studies have focused on their in vivo fate. Similarly, although we have previously reported the increased in vitro uricolytic activity (about 2.2 times higher than that of free uricase, or three times higher than that of PEGylated uricase, Puricase(®), under physiological pH and temperature) and improved stability of the novel alkaline enzymosomes (functional lipid vesicles encapsulating uricase from Candida utilis: uricase-containing lipid vesicles, UOXLVs), it is still necessary to study the biological properties and hypouricemic effects of UOXLVs in vivo. METHODS: The enzyme kinetics, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary safety of UOXLVs were evaluated. RESULTS: The Michaelis constant (K(m)) value of the UOXLVs was slightly lower than that of the free enzyme. The enzyme release from the UOXLVs lasted over 12 hours and their circulation half-life was about sevenfold longer than that of the free uricase. Meanwhile, the UOXLVs had a 22-fold increase in the area under the curve compared with the free uricase. Furthermore, it took less than 3 hours for the UOXLVs to lower the plasma uric acid concentration from a high to a normal level, compared with 6 hours for the free uricase. In addition, the UOXLVs had much less immunogenicity than free uricase and were well tolerated by all animals throughout the observation period. CONCLUSION: The UOXLVs markedly improved the biological properties and enhanced the hypouricemic effects of uricase in vivo.
Asunto(s)
Candida/enzimología , Portadores de Fármacos/química , Urato Oxidasa/química , Ácido Úrico/metabolismo , Alantoína/sangre , Alantoína/metabolismo , Animales , Portadores de Fármacos/farmacocinética , Portadores de Fármacos/farmacología , Estabilidad de Enzimas , Hemólisis/efectos de los fármacos , Concentración de Iones de Hidrógeno , Cinética , Masculino , Ratas , Ratas Sprague-Dawley , Urato Oxidasa/metabolismo , Urato Oxidasa/farmacología , Ácido Úrico/sangreRESUMEN
The aim of this study was to assess the potential of a novel alkaline enzymosome to deliver uricase from Bacillus fastidious (UBF) and enhance its biochemical and pharmacological characteristics. The in vitro catalytic activity of the UBF loaded in the novel alkaline enzymosomes (ESUBFs) was almost 3.8 times that of free UBF at the optimum pH or 1.5 times that of free UBF at the physiological pH. Following intravenous (i.v.) administration (2000 mU/kg) in rats, ESUBFs provided significantly higher (22.5-fold) area under the plasma concentration (AUC) and longer (8.2-fold) circulation half-life (t(1/2)) compared with free UBF, respectively. Further, it took only 4.5h (or 1.1h) for ESUBFs to lower the plasma uric acid concentration from a high level to the normal level of rat (or human beings), compared with 7.6h (or 5.4h) for free UBF. Our results showed that ESUBFs could efficiently deliver UBF and favorably modify its biochemical and pharmacological characteristics by increasing the AUC, t(1/2), and catalytic activity. Therefore, ESUBFs might be a preferred alternative to cure hyperuricemia and gout.
Asunto(s)
Bacillus/enzimología , Hiperuricemia/tratamiento farmacológico , Urato Oxidasa/farmacología , Ácido Úrico/sangre , Animales , Modelos Animales de Enfermedad , Semivida , Humanos , Concentración de Iones de Hidrógeno , Inyecciones Intravenosas , Liposomas , Masculino , Conejos , Ratas , Ratas Sprague-Dawley , Factores de TiempoRESUMEN
Epidemiological, experimental and clinical studies support a role for uric acid in acute kidney injury (AKI). We discuss how the conventional role of uric acid in AKI has now evolved from intratubular crystal deposition to pro-inflammatory, anti-angiogenic and immunological function. Data from recent studies are presented to support the hypothesis that uric acid may have a role in AKI via a crystal-independent process in addition to its traditionally accepted role to induce injury via crystal-dependent pathways.
Asunto(s)
Lesión Renal Aguda/epidemiología , Lesión Renal Aguda/prevención & control , Inhibidores de la Angiogénesis/sangre , Hiperuricemia/tratamiento farmacológico , Modelos Biológicos , Urato Oxidasa/farmacología , Ácido Úrico/sangre , Lesión Renal Aguda/etiología , Inhibidores de la Angiogénesis/inmunología , Animales , Cisplatino/administración & dosificación , Cisplatino/farmacología , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Hiperuricemia/complicaciones , Riñón/irrigación sanguínea , Riñón/efectos de los fármacos , Proyectos Piloto , Ratas , Urato Oxidasa/administración & dosificación , Ácido Úrico/inmunología , Vasoconstricción/efectos de los fármacosRESUMEN
Tumor lysis syndrome (TLS) is a common oncologic emergency in patients with hematological malignancies sensitive to cytotoxic treatment that present a high proliferative rate. High proliferative cancer rate, high sensitivity of cytotoxic treatment and renal failure represent risk factors for development of TLS. TLS is also responsible for several electrolytic alterations, such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. There are different established therapeutic options for the treatment of TLS such as hydration, allopurinol and rasburicase. Rasburicase reduces uric acid levels within 4 h, both in pediatric and adult patients, catalyzing the oxidation of uric acid into allantoin, rapidly excreted by the kidneys. Rasburicase is well tolerated and was approved in the EU and in the USA for the management of acute hyperuricemia.
Asunto(s)
Neoplasias Hematológicas/tratamiento farmacológico , Neoplasias Hematológicas/patología , Síndrome de Lisis Tumoral/tratamiento farmacológico , Urato Oxidasa/uso terapéutico , Humanos , Síndrome de Lisis Tumoral/metabolismo , Síndrome de Lisis Tumoral/patología , Urato Oxidasa/farmacología , Ácido Úrico/metabolismoRESUMEN
Gout has been recognized for centuries but is also a modern day scourge. It is the most common type of inflammatory arthritis in men and appears to be increasing in both incidence and prevalence (Arromdee et al. in J Rheumatol 29(11):2403-2406, 2002). Despite these facts, few advances have been made in the diagnosis and treatment of gout for over 50 years. Difficult cases of gout challenge available therapeutic options. It is only recently that the Food and Drug Administration has approved febuxostat as a treatment option for patients intolerant of allopurinol. We describe a difficult case of tophaceous gout notable for several reasons: utilization of rasburicase as uricolytic treatment to dramatically reduce tissue urate burden; treatment of gout flares with interleukin-1ß inhibition; and quantification of tissue urate with novel dual energy computed tomography technology before and after uricolytic therapy.
Asunto(s)
Gota/diagnóstico por imagen , Gota/tratamiento farmacológico , Articulaciones de la Mano/diagnóstico por imagen , Tomografía Computarizada por Rayos X/métodos , Urato Oxidasa/uso terapéutico , Ácido Úrico/metabolismo , Articulación de la Muñeca/diagnóstico por imagen , Gota/metabolismo , Supresores de la Gota/farmacología , Supresores de la Gota/uso terapéutico , Articulaciones de la Mano/efectos de los fármacos , Articulaciones de la Mano/metabolismo , Humanos , Proteína Antagonista del Receptor de Interleucina 1/farmacología , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Interleucina-1beta/antagonistas & inhibidores , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Urato Oxidasa/farmacología , Articulación de la Muñeca/efectos de los fármacos , Articulación de la Muñeca/metabolismoRESUMEN
Tumor lysis syndrome (TLS) is an oncological emergency consisting of several metabolic derangements: hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. The rupture of tumor cells in cancer patients can be spontaneous or caused by anticancer therapy. Clinical manifestations of TLS include nausea, anorexia, arrhythmias or renal failure. Prevention and treatment measures include aggressive hydration and concomitant antihyperuricemic therapy. Allopurinol has historically been the only available pharmacological option. Rasburicase was subsequently approved for the management of elevated plasma uric acid levels in adults. This recombinant urate oxidase converts uric acid to allantoin, a more soluble byproduct that is safely eliminated by the kidneys. Manufacturer-labeled dosing for rasburicase in the pediatric and adult populations is 0.2 mg/kg as a daily intravenous (i.v.) infusion for up to 5 days. This review summarizes several studies suggesting that flat, single rasburicase dosing regimens may be just as effective as weight-based dosing. The optimal, most cost-effective adult dose and schedule have yet to be determined.